Journal Mobile Options
Table of Contents
Vol. 56, No. 3, 2010
Issue release date: April 2010
Ann Nutr Metab 2010;56:225–232

Glycogen Storage Disease Type 1: Impact of Medium-Chain Triglycerides on Metabolic Control and Growth

Das A.M. · Lücke T. · Meyer U. · Hartmann H. · Illsinger S.
Department of Paediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Hannover, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background/Objective: Hypoketotic hypoglycaemia and hypertriglyceridaemia are biochemical hallmarks of glycogen storage disease (GSD) 1. Increased malonyl coenzyme A production which compromises oxidation of long-chain fatty acids via carnitine palmitoyltransferase (CPT) 1 inhibition plays a crucial role in the pathogenesis of these complications. Therapy consists primarily of nutritional support including frequent carbohydrate-rich meals. We studied the effect of a diet enriched in medium-chain triglycerides (MCT) on metabolic control/growth in GSD 1 as medium-chain fatty acids can be oxidised independently of CPT 1. Methods: An adult female, a 1.6-year-old boy with GSD 1a and a 6.5-year-old girl with GSD 1b treated with a classical GSD diet were enrolled; their ‘classical GSD diet’ was supplemented with MCT fats. Concentrations of glucose, lactate, ketone bodies triglycerides, uric acid, acylcarnitines in blood and organic acids in urine were determined. Results: No clinical or biochemical side-effects were observed. The MCT diet led to a decrease in uric acid concentrations in all patients. Triglyceride levels were reduced only in the youngest patient, while lactate concentrations did not significantly decrease. The MCT diet allowed for a reduction in carbohydrate and caloric intake required to maintain euglycaemia and led to improvement in growth in the two prepubertal patients. Conclusions: MCT supplementation had a positive effect on metabolic control and growth in our patients suffering from GSD 1.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Chen YT: Glycogen storage disease; in Scriver CR, Baudet AL, Valle D, Sly WS (eds): The metabolic and molecular bases of inherited disease. New York, McGraw-Hill, 2001, vol 1, pp 1521–1551.
  2. Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GP: Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 2002;161(suppl 1):S20–S34.

    External Resources

  3. Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GP: Guidelines for management of glycogen storage disease type I – European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 2002;161(suppl 1):S112–S119.
  4. Visser G, Rake JP, Labrune P, Leonard JV, Moses S, Ullrich K, Wendel U, Smit GP: Consensus guidelines for management of glycogen storage disease type 1b – European Study on Glycogen Storage Disease Type 1. Eur J Pediatr 2002;161(suppl 1):S120–S123.

    External Resources

  5. Olpin SE: Implications of impaired ketogenesis in fatty acid oxidation disorders. Prostaglandins Leukot Essent Fatty Acids 2004;70:293–308.
  6. Rasmussen BB, Holmback UC, Volpi E, Morio-Liondore B, Paddon-Jones D, Wolfe RR: Malonyl coenzyme A and the regulation of functional carnitine palmitoyltransferase-1 activity and fat oxidation in human skeletal muscle. J Clin Invest 2002;110:1687–1693.
  7. Binkiewicz A, Senior B: Decreased ketogenesis in von Gierke’s disease (type I glycogenosis). J Pediatr 1973;83:973–978.
  8. Wanders RJ, Vreken P, den Boer ME, Wijburg FA, van Gennip AH, Ijlst L: Disorders of mitochondrial fatty acyl-CoA beta-oxidation. J Inherit Metab Dis 1999;22:442–487.
  9. Foster DW: The role of the carnitine system in human metabolism. Ann NY Acad Sci 2004;1033:1–16.
  10. Roe CR, Ding JH: Mitochondrial fatty acid oxidation disorders; in Scriver CR, Baudet AL, Valle D, Sly WS (eds): The Metabolic and Molecular Bases of Inherited Disease. New York, McGraw-Hill, 2001, vol 2, pp 2297–2326.
  11. Tong L: Acetyl-coenzyme A carboxylase: crucial metabolic enzyme and attractive target for drug discovery. Cell Mol Life Sci 2005;62:1784–1803.
  12. Bandsma RH, Prinsen BH, van Der Velden Mde S, Rake JP, Boer T, Smit GP, Reijngoud DJ, Kuipers F: Increased de novo lipogenesis and delayed conversion of large VLDL into intermediate density lipoprotein particles contribute to hyperlipidemia in glycogen storage disease type 1a. Pediatr Res 2008;63:702–707.
  13. Cuttino JT Jr, Summer GK, Hill HD Jr, Mitchell BJ: Response to medium chain triglycerides in von Gierke’s disease. Pediatrics 1970;46:925–929.

    External Resources

  14. Nagasaka H, Hirano K, Ohtake A, Miida T, Takatani T, Murayama K, Yorifuji T, Kobayashi K, Kanazawa M, Ogawa A, Takayanagi M: Improvements of hypertriglyceridemia and hyperlacticemia in Japanese children with glycogen storage disease type Ia by medium-chain triglyceride milk. Eur J Pediatr 2007;166:1009–1016.
  15. Lockitch G, Halstead AC, Albersheim S, MacCallum C, Quigley G: Age- and sex-specific pediatric reference intervals for biochemistry analytes as measured with the Ektachem-700 analyzer. Clin Chem 1988;34:1622–1625.
  16. Havel RJ, Kane JP: Introduction: structure and metabolism of plasma lipoproteins; in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic and Molecular Bases of Inherited Disease. New York, McGraw Hill, 2001, vol 2, pp 2705–2716.
  17. Hesse V, Jaeger U, Vogel H, Kromeyer K, Zellner K, Bernhardt I, Deichl A: Wachstumsdaten deutscher Kinder von der Geburt bis zu 18 Jahren. Sozialpädiatrie 1997;19: 20–22.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50